Index,Database,Title,Authors,Year,Journal,Accession,GeneAffected,Gene_OMIM_ID,Mutation_description,Mutation_refseq,CMT_subtypes,HPO_genotypeORspecific,HPO_term_IDs,Disease_OMIM_ID,target_HPO,StudyType,PatientsPerGroup,PatsPerGroup_NUMERIC,AgeRange,DrugName,Dose,Delivery,Frequency,Duration_decription,Duration_months,TargetEffect,TargetEffectDescription,ClinicalEffect,ClinicalEffectDescription,Randomised_TF,AppropriateRandomisation_TF,DoubleBlinding_TF,AppropriateDoubleBlinding_TF,DropoutsDescribed_TF,JADAD_score,OCEBM_description,OCEBM_level,Licensed_TF,LicensedNotes
2,PUBMED,Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C,"M. T. Auranen, J.;Suriyanarayanan, S.;Lone, M. A.;Paetau, A.;Tyynismaa, H.;Hornemann, T.;Ylikallio, E.",2017,Cold Spring Harb Mol Case Stud,29042446,SPTLC2,605713,c.547C>T ,NM_004863.3,HSAN1C,genotype,HP:0001324 HP:0002936,612640,HP:0001324 HP:0002936,case study,1,1,67-67,L-serine,daily doses of 50/100/200/300/400 mg/kg/day raised at 3 week intervals to maximum of 400,oral,not described,1 year,12,pos,decreased 1-deoxySO,nc,slight increase in CMTNS score,0,0,0,0,0,0,case study ,4,n,n/a
83,PUBMED,Effect of oral curcumin on Dejerine-Sottas disease,"J. J. Burns, P. D.;Rose, K. J.;Ryan, M. M.;Ouvrier, R. A.",2009,Pediatr Neurol,19748054,PMP22,601097,c.215C>T (p.Ser72Leu),NM_000304.4(PMP22),CMT3,phenotype,HP:0001324 HP:0002936 HP:0002795,145900,HP:0001324 HP:0002795,case study ,1,1,15,curcumin (diferulmethane) ,50-75mg/kg/day,oral,2/day,1 month,1,nc,neurophysiology,nc,"no change in muscle strength, respiratory function, extremity disability or quality of life",0,0,0,0,0,0,case study ,4,n,n/a
123,PUBMED,Episodic weakness and Charcot-marie-tooth disease due to a mitochondrial MT-ATP6 mutation,"F. B. T. Panosyan, R.;Herrmann, D. N.",2017,Muscle Nerve,27783406,MT-ATP6,516060,m.9185T>C (p.Leu220Pro),NC_012920.1,CMT2,phenotype,HP:0001324 HP:0003752,551500,HP:0003752,case series,2,2,34-64,acetazolamide,250-750mg ,oral ,2/d,30 years,360,n/a,n/a,pos,decreased frequency & severity of episodic weakness,0,0,0,0,0,0,case series,4,y,licensed for other diseases
128,PUBMED,"High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial","R. A. M. Lewis, M. P.;Herrmann, D. N.;Hoke, A.;Clawson, L. L.;Siskind, C.;Feely, S. M.;Miller, L. J.;Barohn, R. J.;Smith, P.;Luebbe, E.;Wu, X.;Shy, M. E.",2013,JAMA Neurol,23797954,PMP22,601097,dup,,CMT1A,genotype,HP:0001324 HP:0002936,118220,HP:0001324 HP:0002936,randomised controlled trial,"85 (69 intervention, 16 placebo)",69,13-70,ascorbic acid,4g,oral,1/d,2 years,24,nc,no change in PMP22 mRNA levels,nc,no significant change in CMTNS compared to placebo group ,1,1,1,1,1,5,randomised controlled trial,2,y,licensed for other diseases
132,PUBMED,"Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial","J. O. Burns, R. A.;Yiu, E. M.;Joseph, P. D.;Kornberg, A. J.;Fahey, M. C.;Ryan, M. M.",2009,Lancet Neurol,19427269,PMP22,601097,dup,,CMT1A,genotype,HP:0001324 HP:0002936 HP:0040129,118220,HP:0040129,randomised controlled trial,"81 (42 intervention, 39 placebo)",42,2-16y,ascorbic acid,30mg/kg,oral ,1/d,1 year,12,nc,no change/small non-significant increase in median nerve motor conduction velocity compared with placebo group,nc,"no change in neurophysiological, strength, function, or quality of life outcomes compared with placebo group",1,1,1,1,1,5,randomised controlled trial,2,y,licensed for other diseases
242,PUBMED,"Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial","J. A. Micallef, S.;Dubourg, O.;Gonnaud, P. M.;Hogrel, J. Y.;Stojkovic, T.;Bernard, R.;Jouve, E.;Pitel, S.;Vacherot, F.;Remec, J. F.;Jomir, L.;Azabou, E.;Al-Moussawi, M.;Lefebvre, M. N.;Attolini, L.;Yaici, S.;Tanesse, D.;Fontes, M.;Pouget, J.;Blin, O.",2009,Lancet Neurol,19818690,PMP22,601097,dup,,CMT1A,genotype,HP:0001324 HP:0002936,118220,HP:0001324 HP:0002936,randomised controlled trial,"179 (61 intervention dose 3g, 56 intervention dose 1g, 62 placebo)",56,18-70,ascorbic acid,1-3g,oral,1/d,1 year,12,n/a,n/a,nc,no significant change in CMTNS compared to placebo group ,1,1,1,1,1,5,randomised controlled trial,2,y,licensed for other diseases
243,PUBMED,"Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial","C. d. H. Verhamme, R. J.;Vermeulen, M.;Baas, F.;de Visser, M.;van Schaik, I. N.",2009,BMC Med,19909499,PMP22,601097,dup,,CMT1A,genotype,HP:0001324 HP:0002936,118220,HP:0001324 HP:0002936,randomised controlled trial,"13 (6 intervention, 7 placebo)",6,12-25y,ascorbic acid,1g,oral,2/d,1 year ,12,nc,no significant change in median nerve conduction velocities compared with placebo group,nc,"no significant change in muscle strength, sensory function, CMTNS or disability compared to placebo group ",1,1,1,1,1,5,"randomised controlled trial, but small sample (13 patients)",2,y,licensed for other diseases
248,PUBMED,Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease,"C. A. C. Smith, R. D.;Gutmann, L.;Yeater, R. A.;Alway, S. E.",2006,Muscle Nerve,16881064,PMP22,601097,dup,,CMT1A,phenotype,HP:0001324 HP:0002936,118220,HP:0001324,randomised controlled trial,18,18,"not described, mean age 44 ± 9 SEM",creatine monohydrate + exercise (resistance training),5g,oral,1/d,12 weeks ,3,pos,significant decrease in MHC type I compared with placebo ,pos,decrease in chair rise-time (increase in muscle strength) compared with placebo ,1,1,1,1,1,5,"randomised controlled trial, but small sample (18 patients) & not all patients genetically confirmed CMT1A (only 12/18)",2,n,n/a
389,PUBMED,Hyperdopaminergic crises in familial dysautonomia: a randomized trial of carbidopa,"L. M. Norcliffe-Kaufmann, J.;Axelrod, F.;Kaufmann, H.",2013,Neurology,23553478,ELP1,603722,donor splice site of intron 20,,HSAN3,phenotype,HP:0002936 HP:0002017,223900,HP:0002017,randomised controlled trial,12,12,12-36y ,carbidopa,200mg,oral,3/d,4 weeks,1,n/a,n/a,pos,decreased nausea & retching compared with placebo,1,1,1,1,1,5,randomised controlled trial,2,y,licensed for other diseases
521,PUBMED,A child with night blindness: preventing serious symptoms of Refsum disease,"A. S. Kohlschutter, R.;Lukacs, Z.;Altenburg, C.;Kemper, M. J.;Ruther, K.",2012,J Child Neurol,22156782,PHYH ,602026,c.830C>A (p.Ala277Glu),??,Refsum disease,genotype,HP:0001324 HP:0002936 HP:0001251 HP:0000662 HP:0000505,266500,HP:0001324 HP:0002936 HP:0000505,case study ,1,1,14,phytanic acid-poor diet + extracorporeal lipid apharesis ,n/a,n/a,apharesis 1/month,5 years ,60,pos,decrease in blood phytanic acid levels,pos,decrease in neurological & ophthalmological disease progression ,0,0,0,0,0,0,case study ,4,n/a,n/a
559,PUBMED,"Refsum disease due to the splice-site mutation c.135-2A>G before exon 3 of the PHYH gene, diagnosed eight years after detection of retinitis pigmentosa","J. R. Finsterer, G.;Voigtlander, T.",2008,J Neurol Sci,17905308,PHYH ,602026,"c.135-2A>G, c.153C>T","NM_006214.4, NM_006214.4",Refsum disease,genotype,HP:0001324 HP:0002936 HP:0001251 HP:0000662,266500,not described (HP:0009830),case study ,1,1,55,phytanic acid-poor diet (Chelsea diet),n/a,n/a,n/a,not described,,pos,slight decrease in blood phytanic acid levels,pos,decrease in symptoms (subjective),0,0,0,0,0,0,case study,4,n/a,n/a
585,PUBMED,A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia,"B. E. E. Bar-Aluma, O.;Kaufmann, H.;Palma, J. A.;Norcliffe-Kaufmann, L.",2018,Lung,29234869,ELP1,603722,c.2204+6T>C,NM_003640.5,HSAN3,phenotype,HP:0002936 HP:0002795,223900,HP:0002795,randomised controlled trial ,14,14,16-55,"albuterol sulfate, ipratropium bromide","0.083%, 2.5 mg/3 ml albuterol sulfate, 0.02%, 500 mcg/2.5 ml ipratropium bromide",nebulised,not described,not described,,pos,"increase in FEV1 & FVC, & decrease in airway resistance ",pos,decrease in airway obstruction,1,1,1,1,1,5,randomised controlled study,4,y,licensed for other diseases
765,PUBMED,Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial,"J. L. S. Berk, O. B.;Obici, L.;Sekijima, Y.;Zeldenrust, S. R.;Yamashita, T.;Heneghan, M. A.;Gorevic, P. D.;Litchy, W. J.;Wiesman, J. F.;Nordh, E.;Corato, M.;Lozza, A.;Cortese, A.;Robinson-Papp, J.;Colton, T.;Rybin, D. V.;Bisbee, A. B.;Ando, Y.;Ikeda, S.;Seldin, D. C.;Merlini, G.;Skinner, M.;Kelly, J. W.;Dyck, P. J.",2013,Jama,24368466,TTR,176300,"c.148G>A, p.Val50Met (Val30Met) + non-V30M: L58H, T60A, S50R, F64L, D38A, S77Y, E89Q, V122I, V30G, V32A, K35N, K35T, E42G, F44S, T49P, E54Q, V71A, Y78F, I84N, A97S, I107F ",NM_000371.3 (V30M),ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936,randomised controlled trial,130 (71 V30M + 59 non-V30M),71,"not described, mean 59.7 ",diflunisal ,250mg,oral,2/d,2 years,24,pos,"increase in NIS+7 score, decrease in SF-36 physical score & increase in SF-36 mental score compared with placebo ",pos,decrease in rate of progression of neuological impairment & increase in quality of life,1,1,1,1,1,1,"randomised controlled trial, but 67 patients discontinued intervention during study (high attrition)",2,y,licensed for other diseases
775,PUBMED,Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report,"T. M. Kon, Y.;Nishijima, H.;Honda, M.;Suzuki, C.;Baba, M.;Inomata, Y.;Obayashi, K.;Ando, Y.;Tomiyama, M.",2015,Amyloid,26123280,TTR,176300,c.224T>C (p.Leu75Pro),NM_000371.3,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,case study,1,1,31,tafamidis (+ liver transplant),not described,not described,not described,1 year,12,n/a,n/a,pos/nc,decrease in rate of progression of polyneuropathy & cardiac amyloidosis ,0,0,0,0,0,0,case study,4,y,licensed for TTR-FAP
791,PUBMED,Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report,"T. I. Fujita, T.;Kaida, T.;Iida, Y.;Ikeda, Y.;Nabeta, T.;Ishii, S.;Maekawa, E.;Naruke, T.;Koitabashi, T.;Kitamura, E.;Sekijima, Y.;Ako, J.",2017,Cardiology,28152524,TTR,176300,,NM_000371.3,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0100639 HP:0001638,case study,1,1,72,tafamidis meglumine,20mg (12.2mg tafamidis),oral,1/d,2 years,24,nc,no change in nerve conduction ,nc/neg,"no change in progression of axonopathy, increase in progression of amyloid cardiopymopathy  ",0,0,0,0,0,0,case study,4,y,licensed
835,PUBMED,Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area,"A. V. Cortese, G.;Luigetti, M.;Russo, M.;Bisogni, G.;Sabatelli, M.;Manganelli, F.;Santoro, L.;Cavallaro, T.;Fabrizi, G. M.;Schenone, A.;Grandis, M.;Gemelli, C.;Mauro, A.;Pradotto, L. G.;Gentile, L.;Stancanelli, C.;Lozza, A.;Perlini, S.;Piscosquito, G.;Calabrese, D.;Mazzeo, A.;Obici, L.;Pareyson, D.",2016,J Neurol,26984605,TTR,176300,"c.148G>A, p.Val50Met (Val30Met) + non-V30M: Glu89Gln, Thr49Ala, Tyr78Phe, Ala120Ser, Glu54Gln, Ile68Leu, Ser77Tyr, Ala45Th",,ATTR-FAP,,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,cohort study ,61,61,31-81,tafamidis megluime ,20mg ,oral,1/d,3 years,36,n/a,n/a,nc/pos,"no change in neuropathy & cardiomyopathy progression in V30M, decrease in rate of neuropathy progression after 6 months of treatment in non-V30M & high disability patients ",0,0,0,0,1,1,cohort study ,3,y,licensed 
878,PUBMED,The First Case of Riboflavin Transporter Deficiency in sub-Saharan Africa,"S. Z. Chaya, M.;Gray, D.;Booth, J.;Riordan, G.;Ndondo, A.;Fieggen, K.;Rusch, J.;van der Watt, G.;Pillay, K.;van der Westhuizen, F.;Menezes, M.;Wilmshurst, J.",2018,Semin Pediatr Neurol,29961494,SLC52A3,613350,"c.639C> (p.Tyr213Ter), c.374C>A (p.Thr125Asn)",??,BVVLS,genotype,HP:0001324 HP:0010871 HP:0000365 HP:0000572,211530,HP:0001324,case study,1,1,11 months,riboflavin,80 mg/kg,oral,1/d,3 months,3,pos,increased EGRAC & riboflavin levels,pos/nc,slight increase in motor function ,0,0,0,0,0,0,case study,4,y,licensed
908,PUBMED,"Tafamidis for Transthyretin Familial Amyloid Polyneuropathy: A Randomized, Controlled Trial","T. Coelho, L.F. Maia, A. Martins de Silva, et al,",2012,Neurology,22843282,TTR,176300,"c.148G>A, p.Val50Met (Val30Met)",NM_000371.3,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012 HP:0100639,105210,HP:0001324 HP:0002936,randomised controlled trial,128,128,18-75,tafamidis,20mg,oral,1/d,18 months,18,pos,TTR stabilisation ,pos/nc,"no significant change in NIS-LL or TQOL, but significant delay in progression of peripheral neurolgic impairment ",1,1,1,1,1,5,randomised controlled trial,2,y,licensed 
971,PUBMED,Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years,"F. A. J. Barroso, D. P.;Ebede, B.;Li, H.;Stewart, M.;Amass, L.;Sultan, M. B.",2017,Amyloid,28758793,TTR,176300,"c.148G>A, p.Val50Met (Val30Met); + non V30M",NM_000371.3,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 ,open label extension study ,93 (75 V30M + 18 non-V30M) ,75,not described,tafamidis,20mg/d,oral,1/d,6 years,72,n/a,n/a,pos/nc,significant delay in porgression of neuroogic impairment ,0,0,0,0,1,1,open label extension study,3,7,licensed for TTR-FAP
1069,PUBMED,A novel gain-of-function Nav1.7 mutation in a carbamazepine-responsive patient with adult-onset painful peripheral neuropathy,"T. E. Adi, M.;Schulman, B. R.;Vernino, S.;Dib-Hajj, S. D.;Waxman, S. G.",2018,Mol Pain,30392441,"SCN9A, SCN5A","603415, 600163","c. 2428G>A, c.1844G>A","NM_002977.3, NM_002977.3",,genotype,HP:0002936 HP:0007021,243000,HP:0002936 HP:0007021,Case Study,1,1,53,carbamazepine ,300 mg/day,oral,1,permenant,,pos,"""Furthermore, steady-state fast inactivation of neither WT nor V810M was affected by CBZ (Table 2). However, both WT and V810M showed a significant increase in use-dependent inhibition in the presence of CBZ (WT: p = 0.0001; V810M: p = 0.002; Table 2, Figure 5(c)). Taken together, these data suggest that CBZ acts in this patient with the V810M mutation via the classical mechanism of use-dependent inhibition and not by activation modulation as previously described for other gain-of-function Nav1.7 mutations""",pos,"""The maximum tolerated dose of 300 mg per day significantly reduced frequency and severity of pain attacks.""",0,0,0,0,0,0,Case study,4,Y,Licensed for epilepsy as a sodium channel blocker
1146,PUBMED,Transthyretin-related hereditary amyloidosis in an Argentinian family with TTR Tyr114Cys mutation,"M. A. N. Aguirre, E. M.;Rugiero, M.;Sorroche, P.;Saez, M. S.;Giunta, D. H.;Posadas-Martinez, M. L.;Boietti, B. R.",2017,Amyloid,28434328,TTR,176300,Tyr114Cys,,,OMIM-based,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105200,HP:0001324 HP:0002936 HP:0001638,Case study,1,1,65,Tafamidis,unknown,unknown,unknown,4months,4,-,-,unknown,"She was treated with tafamidis during four months, but she had to stop due to recurrent vaginal infections, severe urinary tract infections, and admissions with abdominal pain and vomiting.",0,0,0,0,0,0,Case study,4,Y,
1437,WHO ICTRP,"Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A",,2011,,NCT01401257,PMP22,601097,dup,?,CMT1A,genotype,HP:0001324 HP:0002936,118220,HP:0001324 HP:0002936,randomised controlled trial,80,80,18-65,PXT3003 ,"high dose (6mg baclofen, 0.7mg naltrexone and 210mg sorbitol), intermediate dose (1.2 mg baclofen, 0.14 mg naltrexone and 42 mg sorbitol), low dose (0.6 mg baclofen, 0.07 mg naltrexone and 21 mg sorbitol)",oral,1/d,12 months,12,n/a,n/a,pos,decreased CMTNS & ONLS in high dose group,1,1,1,1,1,5,RCT,2,n,n/a
1440,EU CLINICAL TRIALS,"Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study",,2016,,,TTR,176300,"c.148G>A, p.Val50Met (Val30Met)",NM_000371.3,,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,randomised controlled trial,63,63,25-74,Tafamidis,20 mg,oral,1,18 months,18,-,-,pos,change from baseline NSLL LSMean score is reduced at month 12 and 18 timepoints,1,1,1,1,1,5,RCT,2,y,"Licensed in the EU for neuropathy, US for cardiomyopathy only"
1441,EU CLINICAL TRIALS,"APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)",,2018,,,TTR,176300,"c.148G>A, p.Val50Met (Val30Met)",NM_000371.3,,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,randomised controlled trial,77,77,18-84,Patisiran,0.3 mg/kg,intravenous ,1/3week,18 months,18,-,-,pos,change from baseline was reduced in the patisiran vs placebo group in the mNIS+7 neuropathy score,1,1,1,1,1,3,RCT,2,y,authorised by EMA for use in familial amyloidosis
1442,EU CLINICAL TRIALS,An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Transplant,,2018,,,TTR,176300,?,?,,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,randomised controlled trial,12,12,18-84,revusiran,500 mg,oral (presumed(,"5 for 7 days, then once weekly",6 months,6,-,-,study terminated,study terminated,0,0,0,0,1,1,cohort study,3,n/a,study was halted due to higher than expected deaths but there is no proper follow up
1444,EU CLINICAL TRIALS,"A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02",completed,2017,,,TTR,,"c.148G>A, p.Val50Met (Val30Met)",NM_000371.3,,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,randomised controlled trial,27,27,18-84,Patisiran,0.3 mg/kg,intravenous ,1/3week,<24 months,24,pos,92% reduction in serum TTR,pos,Signfiicant improvemet in neuropathy over treatment period,0,0,0,0,1,1,cohort study,3,y,authorised by EMA for use in familial amyloidosis
1446,EU CLINICAL TRIALS,The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis,,2016,,,TTR,176300,non-V30M,??,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,open-label trial,21,21,43-76,Tafamidis,20mg,PO,1/d,1.5-12 months,12,pos,TTR stabilisation at 6 weeks & 12 months after treament onset,n/a,n/a,0,0,0,0,1,1,open label study,3,y,licensed for other diseases
1523,COCHRANE TRIALS,"Evaluation of quality of life and disability in patients with hereditary transthyretin-mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic: results from the phase 3 apollo study","D. G.-D. Adams, A.O'Riordan, W.Yang, C. C.Yamashita, T.Kristen, A.Tournev, I.Schmidt, H.Coelho, T.Berk, J. L.et al.,",2018,Neurology,CN-01608719,TTR,176300,"c.148G>A, p.Val50Met (Val30Met); + non-V30M",,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0001638,randomised controlled study ,27,27,"58-75y, mean age 69y",patisiran (ALN-TTR02),0.3 mg/kg,intravenous ,1/3wks,18-24 months,24,N/A,N/A,pos ,significant decrease in mNIS+7 (improvement in motor neuropathy) & stability of cardiac measures,0,0,0,0,0,0,open label extension study,3,y,licensed for ATTR-FAP (NICE UK) 
1526,COCHRANE TRIALS,"A multicenter, double-blind, placebocontrolled, pivotal phase III study (PLEOCMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003), for the treatment of CMT1A","S. S. Attarian, T.Van Damme, P.De Visser, M.Thomas, F.Roberts, M.Fouquier, J.Goedkoop, R.Young, P.",2017,Muscle & nerve,CN-01570874,PMP22,601097,dup,,CMT1A,genotype,HP:0001324 HP:0002936,118220,HP:0001324 HP:0002936,randomised controlled trial,323,323,16-65y,PXT3003 ,"5ml (dose 1: 3 mg baclofen, 0.35 mg naltrexone and 105 mg sorbitol; dose 2: 6 mg baclofen, 0.70 mg naltrexone and 210 sorbitol)",oral (liquid solution) ,2/d,15 months,15,N/A,N/A,pos/nc,"significant decrease in ONLS for dose 2, non-significant decrease in ONLS for dose 1 ",1,1,1,1,1,5,randomised controlled trial,2,n,N/A
1582,COCHRANE TRIALS,Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1,"V. S. Fridman, S.Novak, P.David, W.Macklin, E. A.McKenna-Yasek, D.Walsh, K.Aziz-Bose, R.Oaklander, A. L.Brown, R.et al.,",2019,Neurology,CN-01680372,SPTLC1,605712,ask Rita to contact authors? Why??,ask Rita to contact authors?,HSAN1,genotype,HP:0001324 HP:0002936,162400,HP:0001324 HP:0002936,randomised controlled study ,18,18,29.1–80.4y ,L-serine,400mg/kg,oral,1/d,1 year,12,pos,significant decrease in deoxysphinganine levels ,pos,significant decrease in CMTNS compared with placebo ,1,1,1,1,1,5,randomised controlled trial,2,n,N/A
1893,COCHRANE TRIALS,Randomised controlled trial with ascorbic acid in Charcot-Marie-Tooth type 1A: results of the CMT-TRIAAL/CMT-TRAUK,"D. R. Pareyson, M. M.Schenone, A.Fabrizi, G. M.Cavallaro, T.Santoro, L.Vita, G.Quattrone, A.Padua, L.Gemignani, F.et al.,",2011,Journal of the peripheral nervous system,CN-01767482,PMP22,601097,dup,,CMT1A,genotype,HP:0001324 HP:0002936,118220,HP:0001324 HP:0002936,randomised controlled trial,277,277,18-70y,ascorbic acid,1.5h,oral,1/d,24 months,24,N/A,N/A,nc,no significant change in CMTNS ,1,1,1,1,1,5,randomised controlled trial,2,y,licensed for other diseases
2039,CLINCALTRIALS.GOV,The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin,Completed,2015,Drug: tafamidis,Pfizer,TTR,176300,"c.148G>A, p.Val50Met (Val30Met)",NM_000371.3,,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,,10,10,20-75,Tafamidis,20 mg,oral,1,78 weeks,17,-,-,nc,no observable change in clinical condition scores,0,0,0,0,0,0,Cohort study,4,y,liensed for FAP
2045,PUBMED,"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.",2018,N Engl J Med.,29972753,TTR,176300,"c.148G>A, p.Val50Met (Val30Met); + non-V30M",,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,,225,225,24-83,Patisiran,0.3 mg/kg,intravenous ,1/3weeks,18 months,18,pos,decrease in serum TTR,pos,"decrease vs baseline in mNIS+7 neuropathy score, decrease in baseline for Norffolk QOL-DN score",1,1,1,1,1,5,randomised controlled trial,2,y,licensed for ATTR-FAP (NICE UK) 
2046,PUBMED,Inotersen Treatment for Patients With Hereditary Transthyretin Amyloidosis,"Benson MD, Waddington-Cruz M, Berk JL, et al.",2018,N Engl J Med.,2992757,TTR,176300,"c.148G>A, p.Val50Met (Val30Met); + non-V30M",,ATTR-FAP,genotype,HP:0001324 HP:0002936 HP:0001638 HP:0002012,105210,HP:0001324 HP:0002936 HP:0001638,,172,172,18-83,Inotersen,300mg,intravenous ,"3 in first week, then 1 per week",64 weeks,15,pos,decrease in serum TTR,pos,"decrease vs baseline in mNIS+7 neuropathy score, decrease in baseline for Norffolk QOL-DN score",1,1,1,1,1,5,randomised controlled trial,2,y,licensed for ATTR-FAP (NICE UK) 
2047,PUBMED,Treatable Childhood Neuronopathy Caused by Mutations in Riboflavin Transporter RFVT2,"Foley AR, Menezes MP, Pandraud A, et al.",2014,Brain,24253200,SLC52A2,607882,c.916G>A (p.Gly306Arg),NM_001363118.2,BVVL,genotype,HP:0001324 HP:0002795,211530,HP:0001324 HP:0002795,Case series,2,2,02-Oct,Riboflavin,50mg/kg/day,oral,1/d,not described,,pos,Decreased (normalised) acylcarnitine levels ,pos,"Patient I1: Increased motor & respiratory function in patient I1; 
Patient E1: Same as I1 + decreased visual & hearing impairment in patient ",0,0,0,0,1,1,case series,4,y,Vitamin - not specifically licensed in children but use endorsed by NICE
